Abstract

Background—Hepatic osteodystrophy occurs in the majority of patients with advanced chronic liver disease with the abnormalities in bone metabolism accelerating following orthotopic liver transplantation (OLT).

Aims—To examine changes in bone mineral density (BMD) following OLT and to investigate factors that lead to bone loss.

Methods—Twelve patients had BMD (at both the lumbar spine (LS) and femoral neck (FN)) and biochemical markers measured preoperatively and for 24 months following OLT.

Results—BMD was low in 75% of patients prior to OLT and decreased significantly from baseline at the LS at three months and the FN at six months. BMD began to increase thereafter at both sites, approaching baseline values at the LS by 12 months. Bone formation markers, osteocalcin and procollagen type I carboxy propeptide, decreased immediately post-OLT, with a concomitant increase seen in the resorption markers pyridinoline and deoxypyridinoline. This resulted in a negative uncoupling index early post-OLT, that rebounded to positive values after six months. There was a significant correlation between the change in the uncoupling index between six and three months which preceded the increase in BMD at 12 months. The decrease in BMD recorded early post-OLT correlated with vitamin D levels at three months.

Conclusions—Results suggest that increased resorption and inadequate formation are the major contributors to additional bone loss following OLT. Non-invasive biochemical markers precede later changes in BMD in this patient group following OLT and may have a role in investigating and planning intervention strategies to prevent bone loss in future studies.

(Gut 1999;44:430–434)

Keywords: liver transplantation; bone mineral density; bone resorption

Hepatic osteodystrophy occurs in up to 50% of patients with chronic liver disease and is mainly due to an imbalance between bone formation and bone resorption that results in osteoporosis.\(^1\) Previous studies using biochemical markers of bone formation and resorption have shown that increased resorption is the major contributor to the development of hepatic osteodystrophy.\(^1\) Further bone loss occurs in the first few months following orthotopic liver transplantation (OLT) and results in fracture rates of 17–65% in patients in the first year following OLT.\(^2\) \(^4\) Serial bone mineral density (BMD) measurements performed after OLT show that the greatest loss in bone occurs in the first three to six months.\(^3\) BMD is regained by the end of the first year reaching levels close to preoperative values, increases above baseline values at two years, and continues to increase for up to five years.\(^6\) \(^8\) \(^11\) \(^12\)

No postoperative clinical parameters identify early those patients most at risk of bone loss following OLT;\(^1\) \(^10\) \(^11\) \(^13\) \(^14\) but a low BMD preoperatively seems to predispose to fractures postoperatively.\(^6\) If clinical and/or biochemical parameters could reliably distinguish at risk patients, it may be possible to treat the high risk group with agents to prevent bone loss prior to the development of fractures. An understanding of the mechanism leading to bone loss following OLT is thus required in order to design appropriate treatment schedules.

Histological evidence of increased bone formation at three months following OLT has been found in one study;\(^1\) it was likely that an increase in bone turnover accounted for this finding. Isolated measurements of biochemical markers of bone formation and resorption have revealed an increase in both of these markers following OLT, suggesting an increase in bone turnover rate at this time.\(^1\) \(^9\) \(^11\) Elevated levels of parathyroid hormone (PTH) have been observed in the first three months following surgery, which contribute to an increase in bone resorption.\(^1\) \(^11\) \(^13\) \(^15\) No study has evaluated serial changes in both BMD and bone biomarkers following OLT. Biochemical markers provide a rapid, non-invasive measurement of bone remodelling activity and can be used to calculate the “uncoupling index”, which is the difference or the imbalance between bone formation and resorption.\(^15\) In an osteoporosis intervention trial using a bisphosphonate, alendronate, investigators showed that early changes in bone biomarkers could predict later changes in BMD.\(^15\)

The aim of this study was to document changes in BMD and bone biomarkers in a group of patients following elective OLT for chronic liver disease, to calculate the uncoupling

Abbreviations used in this paper: 25(OH)D, 25-hydroxyvitamin D; ACR, acute cellular rejection; BMD, bone mineral density; DPD, deoxypyridinoline; FN, femoral neck; LS, lumbar spine; OC, osteocalcin; OLT, orthotopic liver transplantation; PICP, procollagen type I carboxy propeptide; PTH, parathyroid hormone; PYD, pyridinoline.
Bone loss following orthotopic liver transplantation

Bone mineral density was measured by dual energy x-ray absorptiometry using a Hologic QDR 1000 scanner. Measurements were taken at the lumbar vertebrae L1–L4 and at the femoral neck, the precision of measurements at these sites being less than 1% and 2% respectively. The results were the composites of T -value, a standard deviation (SD) unit which is calculated as follows:

\[ T -\text{value} = \frac{\text{BMD}_{\text{patient}} - \text{mean BMD}_{\text{reference population}}}{\text{SD}_{\text{reference population}}} \]

A T-value below −2.5 indicates osteoporosis, a T-value between −2.5 and −1.0 represents osteopenia, and values above −1.0 are considered normal, according to World Health Organisation criteria. BMD measurements were performed on all patients prior to OLT (n=12) and at three (n=11), six (n=10), nine (n=8), 12 (n=11), 18 (n=9), and 24 (n=6) months following surgery.

**Bone densitometry**

Bone mineral density was measured by dual energy x-ray absorptiometry using a Hologic QDR 1000 scanner. Measurements were taken at the lumbar vertebrae L1–L4 and at the femoral neck, the precision of measurements at these sites being less than 1% and 2% respectively. The results were the composites of T -value, a standard deviation (SD) unit which is calculated as follows:

\[ T -\text{value} = \frac{\text{BMD}_{\text{patient}} - \text{mean BMD}_{\text{reference population}}}{\text{SD}_{\text{reference population}}} \]

A T-value below −2.5 indicates osteoporosis, a T-value between −2.5 and −1.0 represents osteopenia, and values above −1.0 are considered normal, according to World Health Organisation criteria. BMD measurements were performed on all patients prior to OLT (n=12) and at three (n=11), six (n=10), nine (n=8), 12 (n=11), 18 (n=9), and 24 (n=6) months following surgery.

**Materials and methods**

**Patients**

Twelve patients (five men and seven women; aged 48–65 years) underwent OLT for a variety of chronic liver diseases (table 1). Each patient received 10 mg/kg cyclosporin and 2 mg/kg azathioprine preoperatively and 10 mg/kg methylprednisolone at induction of anaesthesia and at the anhepatic stage of surgery. After OLT, all patients were maintained on corticosteroids (5 mg/kg/day, reduced by 5 mg/week), azathioprine (1 mg/kg/day), and cyclosporin (dose adjusted according to trough levels obtained by whole blood monoclonal assay) to maintain levels at 150–200 µg/l for the first six months and thereafter at 100–150 µg/l. Episodes of acute cellular rejection (ACR) were confirmed histologically and treated with 1 g methylprednisolone for three consecutive days. Two patients were converted from triple immunosuppression with cyclosporin to tacrolimus therapy with corticosteroids because of the development of chronic rejection (at three and four months) and because of hirsutism due to cyclosporin (at three months). Five women were postmenopausal at the time of the study and two were on low dose corticosteroids preoperatively (5 mg/day). None of the patients had a history of bone disease or were on any other medications known to interfere with bone metabolism. Ethical approval was granted by the hospital ethics committee and informed consent obtained from each patient prior to inclusion in the study.

**Table 1 Patient demographics, details of medication, and rejection episodes (n=12)**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age at OLT (years)</th>
<th>Reason for OLT</th>
<th>Immunosuppression schedule</th>
<th>Duration of steroid treatment (months)</th>
<th>Episodes of acute (chronic) rejection</th>
<th>Follow up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>53</td>
<td>PSC</td>
<td>Triple IM for 4/12 then dual IM</td>
<td>24</td>
<td>1 (1)</td>
<td>24</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>54</td>
<td>AIH</td>
<td>Triple IM</td>
<td>6</td>
<td>0</td>
<td>18</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>48</td>
<td>PSC</td>
<td>Triple IM</td>
<td>12</td>
<td>2</td>
<td>24</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>48</td>
<td>Haemochromatosis</td>
<td>Triple IM</td>
<td>14</td>
<td>1</td>
<td>24</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>57</td>
<td>AIH</td>
<td>Triple IM</td>
<td>14</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>56</td>
<td>PBC</td>
<td>Triple IM</td>
<td>18</td>
<td>0</td>
<td>24</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>56</td>
<td>PSC</td>
<td>Triple IM for 3/12 then dual IM</td>
<td>24</td>
<td>2 (1)</td>
<td>24</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>43</td>
<td>AIH</td>
<td>Triple IM for 3/12 then dual IM</td>
<td>18</td>
<td>3</td>
<td>18</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>57</td>
<td>Cryptogenic cirrhosis</td>
<td>Triple IM</td>
<td>6</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>51</td>
<td>PBC</td>
<td>Triple IM</td>
<td>10</td>
<td>2</td>
<td>24</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>51</td>
<td>Antithrombin deficiency</td>
<td>Triple IM</td>
<td>12</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>63</td>
<td>PBC</td>
<td>Triple IM</td>
<td>6</td>
<td>1</td>
<td>6</td>
</tr>
</tbody>
</table>

PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; triple IM, immunosuppression with cyclosporin, azathioprine, and steroids; dual IM, immunosuppression with tacrolimus and steroids.

Bone formation was assessed using serum concentration levels of osteocalcin (OC), which is a non-collagenous protein present in bone matrix, and procollagen type 1 carboxy propeptide (PICP), which is the C terminal end of the procollagen molecule released during collagen formation. Bone resorption was assessed using urinary excretion of free pyridinoline (PYD) and deoxypyridinoline (DPD) crosslinks which are present in mature bone and released into the circulation during bone resorption. Vitamin D and calcium status was assessed by measuring serum 25-hydroxyvitamin D (25(OH)D), total and ionised calcium, phosphate (PO₄), and PTH levels. OC was measured by enzyme immunoassay (Bioscience, Ireland) and free PYD and DPD crosslinks were measured by the Metra Biosystems ELISA method. Urinary calcium was measured by atomic absorption spectroscopy and urinary creatinine on a clinical chemical analyser (Cobas Bio) using the Jaffe reaction. Urinary excretion of free pyridinoline (PYD) and deoxypyridinoline (DPD) crosslinks were expressed per mmol of urinary creatinine and performed on a second void two hour urine sample. The precision for measurements of the various biochemical markers was: 6.1% and 3% for PICP at concentrations of 78 and 132 µg/l respectively, 5.5% and 9.5% for OC at concentrations of 8.1 and 26.2 µg/l respectively, and 7.5% and 5.3% for urine free DPD at 24.6 and 122 nmol/l.

Bone mineral density was measured by dual energy x-ray absorptiometry using a Hologic QDR 1000 scanner. Measurements were taken at the lumbar vertebrae L1–L4 and at the femoral neck, the precision of measurements at these sites being less than 1% and 2% respectively. The results were the composites of T -value, a standard deviation (SD) unit which is calculated as follows:

\[ T -\text{value} = \frac{\text{BMD}_{\text{patient}} - \text{mean BMD}_{\text{reference population}}}{\text{SD}_{\text{reference population}}} \]

A T-value below −2.5 indicates osteoporosis, a T-value between −2.5 and −1.0 represents osteopenia, and values above −1.0 are considered normal, according to World Health Organisation criteria. BMD measurements were performed on all patients prior to OLT (n=12) and at three (n=11), six (n=10), nine (n=8), 12 (n=11), 18 (n=9), and 24 (n=6) months following surgery.

**BIOCHEMICAL MARKERS OF BONE FORMATION AND RESORPTION**

Bone formation was assessed using serum concentration levels of osteocalcin (OC), which is a non-collagenous protein present in bone matrix, and procollagen type 1 carboxy propeptide (PICP), which is the C terminal end of the procollagen molecule released during collagen formation. Bone resorption was assessed using urinary excretion of free pyridinoline (PYD) and deoxypyridinoline (DPD) crosslinks which are present in mature bone and released into the circulation during bone resorption. Vitamin D and calcium status was assessed by measuring serum 25-hydroxyvitamin D (25(OH)D), total and ionised calcium, phosphate (PO₄), and PTH levels. OC was measured by enzyme immunoassay (Bioscience, Ireland) and free PYD and DPD crosslinks were measured by the Metra Biosystems ELISA method. Urinary calcium was measured by atomic absorption spectroscopy and urinary creatinine on a clinical chemical analyser (Cobas Bio) using the Jaffe reaction. Urinary excretion of free pyridinoline (PYD) and deoxypyridinoline (DPD) crosslinks were expressed per mmol of urinary creatinine and performed on a second void two hour urine sample. The precision for measurements of the various biochemical markers was: 6.1% and 3% for PICP at concentrations of 78 and 132 µg/l respectively, 5.5% and 9.5% for OC at concentrations of 8.1 and 26.2 µg/l respectively, and 7.5% and 5.3% for urine free DPD at 24.6 and 122 nmol/l.
respectively. Serum ionised calcium was measured by ion selective electrode with a radiometer ICA2 analyser. Serum 25(OH)D was assayed by radioimmunoassay (Incstar Corp., Stillwater, USA) and PTH by immuno-radiometric analysis (Allegro-Nichols, San Juan Capistrano, USA). All samples were obtained at 10 00 am following an overnight fast and placed on ice and transported to the laboratory immediately following phlebotomy for separation and storage at −20°C until assayed. Biochemical markers were performed on all patients prior to OLT (n=12) and at one (n=9), two (n=5), three (n=9), six (n=10), nine (n=10), 12 (n=11), 18 (n=10), and 24 (n=6) months following surgery.

**Expression of results of biochemical markers**

Results of bone resorption markers were measured per mmol of urinary creatinine and bone formation markers in serum as µg/l. Bone formation and resorption markers were then expressed as SD units (T-values) compared with the mean of a sex matched reference population which included premenopausal women (n=32) and men in the 20–45 year age group (n=20). This system was used to enable a comparison between resorption and formation activities in the patients studied.

**Statistical methods**

Results are given as mean values (SD). Differences between measurements were analysed by the Wilcoxon signed rank test and linear regression analysis was used to examine the correlation between changes in BMD, markers of bone turnover, and demographic variables.

**Results**

**Bone mineral density**

Preoperative BMD T-values at the LS and FN were −1.97 (1.28) and −1.80 (1.1) respectively; 42% of patients met the criteria for osteoporosis and 33% met the criteria for osteopenia.

Following OLT, BMD at the LS decreased significantly at three months (−2.22 (1.23), p<0.05) compared with baseline. BMD at the LS began to increase after six months, with a significant rise seen between six and 12 months (−2.50 (1.01) to −1.92 (0.99), p<0.01) and between 12 and 18 months (−1.66 (−0.97), p<0.05). A slight decrease occurred at 24 months (−2.21 (0.86), NS, n=6). BMD continued to improve in eight of the 12 individuals over the time period of the study (Fig 1). BMD at the FN decreased significantly from baseline by six months (−2.27 (0.71), p<0.01) post-OLT. An increase in BMD was noted at this site at nine and 12 months (−2.16 (1.01) and −2.18 (0.84), NS) with a decrease again noted after this time, at 18 and 24 months (−2.37 (0.77) and −2.52 (0.60), NS) (Fig 1).

**Biomarkers**

**Bone formation**

The T-value for OC at baseline was 1.55 (3.4) and decreased immediately post-OLT. OC began to increase again by three months with a significant increase in values between one and three months (−0.08 (1.62) versus 3.42 (3.9), p<0.05) and continued to increase up to nine months (8.80 (6.2), p<0.01) when it stabilised at a value well above the normal reference range.

At baseline PICP was 2.83 (2.45) and decreased significantly at one month post-OLT (1.03 (1.35), p<0.05); it began to increase at two months (3.82 (4.43), NS), with a significant increase seen between values at one and three months (3.86 (3.6), p<0.05). PICP stabilised after this time and fell to within the normal reference range by 12 months (0.94 (0.68)).

**Bone resorption**

At baseline DPD was 3.61 (2.24) and began to increase immediately post-OLT, reaching a peak at two months (6.75 (4.0), NS); it then stabilised but remained above the normal range (greater than 2.5) for the duration of the study. T-values for both resorption markers, DPD and PYD, correlated significantly with each other at all time points measured (p<0.001).

**Uncoupling index (OC minus DPD)**

The difference between T-values for bone formation and resorption indexes (OC – DPD) was negative at baseline (−2.3 (3.76)), decreased further in the first two months (−5.7 (2.34), NS), then began to rise and was positive by six months (2.03 (4.06)), with a significant increase seen between three and nine months.
Bone loss following orthotopic liver transplantation

After this time the uncoupling index stabilised (r=0.766, p<0.05). There was a significant correlation between the increase in BMD at the LS and FN (between three and 12 months) and the change in the uncoupling index (OC – DPD) between three and six months (LS: r=0.76, p<0.05; and FN: r=0.62, p=0.09), for eight patients who had all measurements performed at these times (fig 3). A significant correlation was also found between the increase in BMD and changes in the uncoupling index, expressed as PICP – DPD, at similar times (LS: r=0.74, p<0.05). The change in the uncoupling index preceded the measured change in BMD and is shown for one patient (fig 4).

VITAMIN D STATUS

Serum 25(OH)D concentrations were below normal (less than 70 nmol/l) at baseline (mean 16.6 (8.75)) and increased following OLT but remained below the normal reference range for the study period. Concentrations increased significantly to 46 (17.2) by three months (p<0.01) and remained relatively stable thereafter. Serum 25(OH)D concentrations at three months correlated with the increase seen in the BMD both at the LS and FN between baseline and six months (LS: r=0.67, p<0.05; and FN: r=0.71, p<0.05). Serum PTH concentrations were within the normal range (less than 5.5 pmol/l) preoperatively (3.61 (2.7)), but began to increase steadily post-OLT; there was a significant increase seen between concentrations at baseline and three months (3.61 (2.7) versus 4.35 (1.5), p<0.05) and between concentrations at six and nine months (4.87 (2.0) versus 6.65 (2.2), p<0.05). The mean value for PTH remained above the upper limit of normal at 5.5 pmol/l for the two years post-OLT.

CLINICAL EVENTS

Patients spent an average of 27 days (range 16–35) in hospital following surgery. ACR was diagnosed 1.33 times (range 0–3) in each patient during the first three months following OLT. Only one episode of ACR occurred after this time. There was no correlation detected between the change in BMD and the number of episodes of ACR or the length of time spent on corticosteroid medication. The correlation between the change in BMD at the FN from baseline to three months with the number of days spent in hospital approached significance (r=0.52, p=0.09).

Discussion

Significant decreases in BMD were seen in the first three to six months following OLT as previously reported. An improvement occurred after this time and values were well above baseline at 12 months for the LS. An unexpected fall in BMD was observed at 18 months for the FN and 24 months for the LS for the group, but a continuous improvement was seen in BMD for eight of the 12 patients. Of the four patients who had a decrease in BMD after 18 months (following an initial improvement), two of these had received further corticosteroid therapy for late ACR and a relapse of ulcerative colitis respectively; the latter also underwent surgery for a small bowel obstruction at 22 months (fig 5). The decrease in BMD seen in the other two patients at the LS only remains unexplained; both remained well with normal liver and renal function and were not commenced on any new medications at this time. This deterioration in BMD emphasises the susceptibility of this already compromised patient group to further deterioration even after an initial improvement had been observed in BMD.

Biochemical markers of bone formation and resorption and the calculated uncoupling index indicated that bone resorption exceeded bone formation in this patient group. The greater specificity of the newer markers of bone turnover is generally accepted, as is their use in epidemiological and interventional research studies. The large within subject variability attributed to the markers is a limitation to their usage in individual patients. The changes observed in the uncoupling index in the first six months correlated with the later changes in BMD and may be a useful technique for identifying at risk groups. Vitamin D status also plays an important role following OLT as shown by the relation between hypovitaminosis
D and bone loss which may reflect compensatory secondary hyperparathyroidism due to inadequate calcium absorption.

Three of the 12 patients were changed from therapy with cyclosporin to tacrolimus during the course of the study because of early chronic rejection (n=2) and hirsutism (n=1). BMD continued to improve in two of these patients and the third had a fall in BMD at 24 months which coincided with corticosteroid therapy for inflammatory bowel disease. It is therefore difficult to conclude whether tacrolimus and cyclosporin had different effects on BMD.

Using non-invasive methods, we have shown that BMD decreased following OLT and is related to a negative uncoupling index. Although this study included a small heterogeneous group of patients the pathogenesis of this bone loss seems to result from an excess of bone resorption relative to formation, as indicated by the negative uncoupling index and its correlation with the loss in BMD at one year. The major risk factors for the development of fractures post-OLT include pre-existing bone loss compounded by the additional bone loss that occurs postoperatively due to immunosuppression and immobility. The common immunosuppressants—corticosteroids, cyclosporin, and tacrolimus—have been shown to have deleterious effects on bone in both animals and man. An adverse effect on BMD by cumulative steroid dosage and/or rejection episodes has not been observed in a consistent manner that suggests individual susceptibility of patients to these risk factors. Some more recent studies have shown less bone loss than previously following liver transplantation, which may be due to the tendency for lower doses of corticosteroids in immunosuppression regimens, in addition to the earlier referral of fitter patients for liver transplantation and improved medical care following surgery. As seen in this study, even after an initial recovery in BMD, further doses of steroids can have dramatic adverse effects on BMD.

The only randomised controlled treatment trial performed on patients following OLT showed an increase in the vertebral BMD with the antiresorptive agents calcitonin (6.4%) and bisphosphonates (8.2%) compared with a loss of 3.4% in the untreated group. A non-randomised trial of cyclical etidronate in combination with vitamin D and calcium did not improve BMD or fracture rates compared with untreated patients. The results of this study would suggest that vitamin D therapy is indicated in all patients post-OLT in view of the notable reduction seen in 25(OH)D at baseline and the correlation observed with the decrease in BMD. Further controlled trials are required to decide which antiresorptive agent is most effective in patients following OLT.

In conclusion, a decline in BMD occurred in this patient group following OLT and was caused by an excess of bone resorption relative to bone formation, which began to reverse at six months. We have shown early changes in bone biochemical markers which correlate significantly with later changes in BMD. Identification of early changes in bone markers may prove useful in planning therapeutic strategies to prevent bone loss in at risk groups.

We would like to acknowledge the assistance of Barbara Murray and Yvonne McMinn, biochemists in the Metabolism Laboratory, and Deirdre O’Sullivan, Kate Frazer and Catherine Dunne, nurses in the Liver Unit, for their help in collecting samples.